Skip to main content
. 2014 Jun 30;32(23):2505–2511. doi: 10.1200/JCO.2013.54.6051

Fig A1.

Fig A1.

Case study, trial one: phase I trial of platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel in patients with prostate cancer. (A) Trial history (dose units are in mg/m2); (B) observed dose-limiting toxicity (DLT) rate at each dose level. Brackets indicate maximum-tolerated dose; squares indicate DLTs; circles indicate observed DLT rate; dashed line indicates acceptable/target DLT rate. Data adapted.35